Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM).
LM Symposium
The jointly sponsored LM presentation and panel discussion was the most attended industry-sponsored symposium of the entire event, underscoring the growing urgency and interest in finding solutions for this devastating complication of advanced cancers.
Request a recording of the symposium here.
Celebrating Recognition & Collaboration
In addition to the symposium:
-
CNSide Diagnostics and Dr. Priya Kumthekar’s FORESEE poster was awarded first place recognition at the conference.
-
Leadership from Plus Therapeutics and CNSide Diagnostics held key onsite meetings with key opinion leaders (KOLs) and patient advocacy groups, building momentum for continued collaboration and innovation in the LM space.
Why This Matters
Leptomeningeal metastases remain a critical unmet need in neuro-oncology, affecting patients across multiple cancer types with limited treatment options. By combining expertise in therapeutics and diagnostics, Plus Therapeutics and CNSide are working together to advance research, improve diagnosis, and expand treatment opportunities.
Looking Ahead
The success at SNO/ASCO 2025 highlights both companies’ commitment to driving progress in CNS cancers and creating new pathways for hope in LM treatment.
Stay connected with us for updates on clinical trials, research data, and future collaborations.
#PlusTherapeutics #CNSide #LeptomeningealMetastases #LM #NeuroOncology #BrainCancer #CNSMetastases #ClinicalTrials #CancerResearch #OncologyInnovation #SNO #ASCO #SNOASCO2025 #PSTV
Recent Comments